Myocardial infarction type 2 and myocardial injury

Clinical Chemistry

Volumn 63, Issue 1, 2017, Pages 101-107

  Sandoval, Yader ^a,b   Thygesen, Kristian ^c  

^a HENNEPIN COUNTY MEDICAL CENTER   (United States)

^b MINNEAPOLIS HEART INSTITUTE FOUNDATION   (United States)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

TROPONIN; BIOLOGICAL MARKER;

CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE MANAGEMENT; HEART INFARCTION; HEART MUSCLE INJURY; HUMAN; MYOCARDIAL INFARCTION TYPE 2; PROGNOSIS; REVIEW; ST SEGMENT ELEVATION; CLASSIFICATION; REPERFUSION INJURY;

BIOMARKERS; HUMANS; MYOCARDIAL INFARCTION; REPERFUSION INJURY; TROPONIN;

EID: 85008517862     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2016.255521     Document Type: Review

References (43)

1. Hammer A. Ein Fall von thrombotischem Verschlusse einer der Kranzarterien des Herzens. Wien Med Wschr 1878;28:97-102.
2. Obraztzow VP, Straschesko ND. Zur Kenntnis der Thrombose der Koronararterien des Herzens. Z Klin Med 1910;71:116-32.
3. Herrick JB. Clinical features of sudden obstruction of the coronary arteries. JAMA 1912;59:2015-22.
4. Friedberg CK, Horn H. Acute myocardial infraction not due to coronary artery occlusion. JAMA 1939;112:1675-9.
5. WHO. Working group on the establishment of ischemic heart disease registers. Report of the fifth working group, Copenhagen. In Report No. Eur 8201 (5). Geneva: WHO; 1971.
6. Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arveiler D, Rajakangas AM, Pajak A. Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and casefatality rates in 38 populations from 21 countries in four continents. Circulation 1994;90:583-612.
7. The Joint European Society of Cardiology/American College of Cardiology Committee: Myocardial infarction redefined - a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. Eur Heart J 2000;21:1502-13;
8. J AmColl Cardiol 2000;36:959-69.
9. Thygesen K, Alpert JS, White HD; Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. Eur Heart J 2007;28:2525-38;
10. Circulation 2007;116:2634-53;
11. J Am Coll Cardiol 2007;50:2173-95.
12. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD; the Writing Group on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction. Third universal definition of myocardial infarction. Eur Heart J 2012;33:2551-67;
13. Circulation 2012;126:2020-35;
14. J Am Coll Cardiol 2012;60:1581-98.
15. Alpert JS, Thygesen KA, White HD, Jaffe AS. Diagnostic and therapeutic implications of type 2 myocardial infarction: review and commentary. Am J Med 2014;127:105-8.
16. Sandoval Y, Smith SW, Thordsen SE, Apple FS. Supply/demand type 2 myocardial infarction: should we be paying more attention? J Am Coll Cardiol 2014;63:2079-87.
17. Baron T, Hambraeus K, Sundström J, Erlinge D, Jernberg T, Lindahl B; Total-AMI study group. Type 2 myocardial infarction in clinical practice. Heart 2015;101:101-6.
18. Baron T, Hambraeus K, Sundström J, Erlinge D, Jernberg T, Lindahl B; Total-AMI study group. Impact on long-term mortality of presence of obstructive coronary artery disease and classification of myocardial infarction. Am J Med 2016;129:398-406.
19. Bonaca MP, Ruff CT, Kosowsky J, Conrad MJ, Murphy SA, Sabatine MS, et al. Evaluation of the diagnostic performance of current and next-generation assays for cardiac troponin I in the MWH-TIMI ED chest pain study. Eur Heart J Acute Cardiovasc Care 2013;2:195-202.
20. Javed U, Aftab W, Ambrose JA, Wessel RJ, Mouanoutoua M, Huang G, et al. Frequency of elevated troponin I and diagnosis of acute myocardial infarction. Am J Cardiol 2009;104:9-13.
21. Melberg T, Burman R, Dickstein K. The impact of the 2007 ESC-ACC-AHA-WHF universal definition on the incidence and classification of acute myocardial infarction: a retrospective cohort study. Int J Cardiol 2010;139:228-33.
22. Morrow DA, Wiviott SD, White HD, Nicolau JC, Bramucci E, Murphy SA, et al. Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38: an application of the classification system from the universal definition of myocardial infarction. Circulation 2009;119:2758-64.
23. Saaby L, Poulsen TS, Hosbond S, Larsen TB, Diederichsen ACP, Hallas J, et al. Classification of myocardial infarction: frequency and features of type 2 myocardial infarction. Am J Med 2013;126:789-97.
24. Sandoval Y, Smith SW, Schulz KM, Murakami MM, Love SA, Nicholson J, Apple FS. Diagnosis of type 1 and type 2 myocardial infarction using a high-sensitivity cardiac troponin I assay with sex-specific 99th percentiles based on the third universal definition of myocardial infarction classification system. Clin Chem 2015;61:657-63.
25. Shah AS, McAllister DA, Mills R, Lee KK, Churchhouse AM, Fleming KM, et al. Sensitive troponin assay and the classification of myocardial infarction. Am J Med 2015;128:493-501.
26. Smith SW, Diercks DB, Nagurney JT, Hollander JE, Miller CD, Schrock JW, et al. Central versus local adjudication of myocardial infarction in a cardiac biomarker trial. Am Heart J 2013;165:273-9.
27. Stein GY, Herscovici G, Korenfeld R, Matetzky S, Gottlieb S, Alon D, et al. Type-II myocardial infarction: patient characteristics, management and outcomes. PLoS One 2014;9:e84285.
28. Szymański FM, Karpiński G, Płatek AE, Majstrak F, Hrynkiewicz-Szymańska A, Kotkowski M, et al. Clinical characteristics, aetiology and occurrence of type 2 acute myocardial infarction. Kardiol Pol 2014;72:339-44.
29. Spatz ES, Curry LA, Masoudi FA, Zhou S, Strait KM, Gross CP, et al. The variation in recovery: role of gender on outcomes of young AMI patients (VIRGO) classification system: a taxonomy for young women with acute myocardial infarction. Circulation 2015;132:1710-8.
30. Gard A, Lindahl B, Baron T. Skillnader i vard av patienter med typ 1-och typ 2-hjärtinfarkt: Riktlinjer för behandling vid typ 2-hjärtinfarkt saknas helt. Lakartidningen 2015; Nov. 24:112.
31. Matsue Y, Yoshida K, Hoshino M, Yonetsu T, Suzuki M, Matsumura A, et al. Clinical features and prognosis of type 2 myocardial infarction in vasospastic angina. Am J Med 2015;128:389-95.
32. Reynolds HR, Srichai MB, Iqbal SN, Slater JN, Mancini GB, Feit F, et al. Mechanisms of myocardial infarction in women without angiographically obstructive coronary artery disease. Circulation 2011;124:1414-25.
33. Sarkisian L, Saaby L, Poulsen TS, Gerke O, Jangaard N, Hosbond S, et al. Clinical characteristics and outcomes of patients with myocardial infarction, myocardial injury, and nonelevated troponins. Am J Med 2016;129:446e.5-446e.21.
34. Sandoval Y, Thordsen SE, Smith SW, Schulz KM, Murakami MM, Pearce LA, Apple FS. Cardiac troponin changes to distinguish type 1 and type 2 myocardial infarction and 180-day mortality risk. Eur Heart J Acute Cardiovasc Care 2014;3:317-25.
35. Sarkisian L, Saaby L, Poulsen TS, Gerke O, Hosbond S, Jangaard N, et al. Prognostic impact of myocardial injury related to various cardiac and noncardiac conditions. Am J Med 2016;129:506-14.
36. Saaby L, Poulsen TS, Diederichsen ACP, Hosbond S, Larsen TB, Schmidt H, et al. Mortality rate in type 2 myocardial infarction: observations from an unselected hospital cohort. Am J Med 2014;127:295-302.
37. Smilowitz NR, Naoulou B, Sedlis SP. Diagnosis and management of type II myocardial infarction: increased demand for a limited supply of evidence. Curr Atheroscler Rep 2015;17:478.
38. Jaffe AS, Moeckel M, Giannitsis E, Huber K, Mair J, Mueller C, et al. In search for the Holy Grail: suggestions for studies to define delta changes to diagnose or exclude acute myocardial infarction: a position paper from the study group on biomarkers of the Acute Cardiovascular Care Association. Eur Heart J Acute Cardiovasc Care 2014;3:313-6.
39. Boeddinghaus J, Reichlin T, Cullen L, Greenslade JH, Parsonage WA, Hammett C, et al. Two-hour algorithm for triage toward rule-out and rule-in of acute myocardial infarction by use of high-sensitivity cardiac troponin I. Clin Chem 2016;62:494-504.
40. Shah ASV, Anand A, Sandoval Y, Lee KK, Smith SW, Adamson PD, et al. High-sensitivity cardiac troponin I at presentation in patients with suspected acute coronary syndrome: a cohort study. Lancet 2015;386:2481-8.
41. Bandstein N, Ljung R, Johansson M, Holzmann MJ. Undetectable high-sensitivity cardiac troponin T level in the emergency department and risk of myocardial infarction. J Am Coll Cardiol 2014;63:2569-78.
42. Jaeger C, Wildi K, Twerenbold R, Reichlin T, Rubini Gimenez M, Neuhaus JD, et al. One-hour rule-in and rule-out of acute myocardial infarction using highsensitivity cardiac troponin I. Am Heart J 2016;171:92-102.
43. Mueller C, Giannitsis E, Christ M, Ordóñez-Llanos J, de-Filippi C, McCord J, et al. Multicenter evaluation of a 0-hour/1-hour algorithm in the diagnosis of myocardial infarction with high-sensitivity cardiac troponin T. Ann Emerg Med 2016;68:76-87. e4.